121 related articles for article (PubMed ID: 32868184)
1. Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis.
McGahan W; Waterhouse MA; O'Connell DL; Merrett ND; Goldstein D; Wyld D; Burmeister EA; Jordan SJ; Neale RE
Pancreatology; 2020 Oct; 20(7):1458-1464. PubMed ID: 32868184
[TBL] [Abstract][Full Text] [Related]
2. Utility of tumor markers in determining resectability of pancreatic cancer.
Schlieman MG; Ho HS; Bold RJ
Arch Surg; 2003 Sep; 138(9):951-5; discussion 955-6. PubMed ID: 12963650
[TBL] [Abstract][Full Text] [Related]
3. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer.
Kiliç M; Göçmen E; Tez M; Ertan T; Keskek M; Koç M
Can J Surg; 2006 Aug; 49(4):241-4. PubMed ID: 16948881
[TBL] [Abstract][Full Text] [Related]
4. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma.
Maithel SK; Maloney S; Winston C; Gönen M; D'Angelica MI; Dematteo RP; Jarnagin WR; Brennan MF; Allen PJ
Ann Surg Oncol; 2008 Dec; 15(12):3512-20. PubMed ID: 18781364
[TBL] [Abstract][Full Text] [Related]
5. Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy.
Connor S; Bosonnet L; Alexakis N; Raraty M; Ghaneh P; Sutton R; Neoptolemos JP
Dig Surg; 2005; 22(1-2):80-5. PubMed ID: 15849467
[TBL] [Abstract][Full Text] [Related]
6. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma.
Zhang S; Wang YM; Sun CD; Lu Y; Wu LQ
World J Gastroenterol; 2008 Jun; 14(23):3750-3. PubMed ID: 18595144
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.
Allen VB; Gurusamy KS; Takwoingi Y; Kalia A; Davidson BR
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD009323. PubMed ID: 27383694
[TBL] [Abstract][Full Text] [Related]
9. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
10. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease.
Ritts RE; Nagorney DM; Jacobsen DJ; Talbot RW; Zurawski VR
Pancreas; 1994 Nov; 9(6):707-16. PubMed ID: 7846013
[TBL] [Abstract][Full Text] [Related]
11. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.
Bloomston M; Bekaii-Saab TS; Kosuri K; Cowgill SM; Melvin WS; Ellison EC; Muscarella P
Pancreas; 2006 Oct; 33(3):246-9. PubMed ID: 17003645
[TBL] [Abstract][Full Text] [Related]
12. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort.
Herreros-Villanueva M; Ruiz-Rebollo L; Montes M; Rodriguez-Lopez M; Francisco M; Cubiella J; Iyo E; Garabitos E; Martínez Moneo E; Martos M; de Madaria E; Martínez-Arránz I; García-Cougil M; Iglesias-Gómez A; Bujanda L
Mol Biol Rep; 2020 Mar; 47(3):1583-1588. PubMed ID: 31915999
[TBL] [Abstract][Full Text] [Related]
13. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
[TBL] [Abstract][Full Text] [Related]
14. Proposed cut-off value of CA19-9 for detecting pancreatic cancer in patients with diabetes: a case-control study.
Murakami M; Nagai Y; Tenjin A; Tanaka Y
Endocr J; 2018 Jun; 65(6):639-643. PubMed ID: 29643268
[TBL] [Abstract][Full Text] [Related]
15. CA19-9 for detecting recurrence of pancreatic cancer.
Azizian A; Rühlmann F; Krause T; Bernhardt M; Jo P; König A; Kleiß M; Leha A; Ghadimi M; Gaedcke J
Sci Rep; 2020 Jan; 10(1):1332. PubMed ID: 31992753
[TBL] [Abstract][Full Text] [Related]
16. Predictive Values of Preoperative Markers for Resectable Pancreatic Body and Tail Cancer Determined by MDCT to Detect Occult Metastases.
Cheng H; Luo G; Jin K; Xiao Z; Qian Y; Gong Y; Yu X; Liu C
World J Surg; 2021 Jul; 45(7):2185-2190. PubMed ID: 33774691
[TBL] [Abstract][Full Text] [Related]
17. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer.
Liu X; Fu Y; Chen Q; Wu J; Gao W; Jiang K; Miao Y; Wei J
BMC Gastroenterol; 2018 Nov; 18(1):168. PubMed ID: 30400836
[TBL] [Abstract][Full Text] [Related]
18. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping.
Luo G; Guo M; Jin K; Liu Z; Liu C; Cheng H; Lu Y; Long J; Liu L; Xu J; Ni Q; Yu X
Pancreatology; 2016; 16(6):1057-1062. PubMed ID: 27692554
[TBL] [Abstract][Full Text] [Related]
19. Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms.
White R; Winston C; Gonen M; D'Angelica M; Jarnagin W; Fong Y; Conlon K; Brennan M; Allen P
J Am Coll Surg; 2008 Mar; 206(3):445-50. PubMed ID: 18308214
[TBL] [Abstract][Full Text] [Related]
20. Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases.
Suker M; Koerkamp BG; Coene PP; van der Harst E; Bonsing BA; Vahrmeijer AL; Mieog JSD; Swijnenburg RJ; Dwarkasing RS; Roos D; van Eijck CHJ
Eur J Surg Oncol; 2019 Oct; 45(10):1906-1911. PubMed ID: 31186205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
